AstraZeneca PLC Appoints New Non-Executive Director

AstraZeneca today announced that Rudy Markham is to join the Board of Directors as a Non-Executive Director with immediate effect. Rudy Markham was formerly Chief Financial Officer of Unilever. He is currently a Non-Executive Director of Legal and General Group Plc, Standard Chartered PLC and United Parcel Service, Inc. He is also a member of Board of the Financial Reporting Council.

Louis Schweitzer, Chairman of AstraZeneca said: “We are delighted that Rudy Markham has agreed to join us. His considerable experience of over 35 years at Unilever, latterly in finance, will be invaluable to the work of the Board and the Audit Committee.”

No disclosure obligations arise under paragraph (1) to (6) of Listing Rule 9.6.13 of the UK Listing Authority’s Listing Rules in respect of the appointment of Rudy Markham.

# # #

12 September 2008

Media Enquiries:
Neil McCrae +44 207 304 5045 (24 hours)
Chris Sampson +44 20 7304 5130 (24 hours)

Investor Enquiries UK:
Jonathan Hunt +44 207 304 5087 mob: +44 7775 704032
Mina Blair +44 20 7304 5084 mob: +44 7718 581021
Karl Hard +44 207 304 5322 mob: +44 7789 654364

Investor Enquiries US:
Ed Seage +1 302 886 4065 mob: +1 302 373 1361
Jorgen Winroth +1 212 579 0506 mob: +1 917 612 4043
Peter Vozzo (MedImmune) +1 301 398 4358 mob: +1 301 252 7518

Notes To Editors

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

Broadcast quality footage is available to download from the Media section of our website at: http://br.thenewsmarket.com/Astrazeneca/br/Login/LoginPreRegistration.aspx

Journalists will be required to register to access this feature.

- Ends -